K. McGraw

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression

M. Calasanz, C. Mecucci, M. Larrayoz, 2015, Leukemia.

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

S. Nahas, J. Lancet, T. Cluzeau, 2016, Leukemia.

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

J. Clark, Sheng Wei, J. Maciejewski, 2013, Oncogene.

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858

Sheng Wei, K. Heider, J. Lancet, 2017, Leukemia.

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858

K. Anderson, Sheng Wei, M. Friedrich, 2017, Leukemia.